» Articles » PMID: 38286716

European Cancer Mortality Predictions for the Year 2024 with Focus on Colorectal Cancer

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2024 Jan 29
PMID 38286716
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We focused on mortality from colorectal cancer (CRC).

Materials And Methods: Based on cancer death certification and population data from the World Health Organization and Eurostat databases from 1970 until the most available year, we predicted deaths and age-standardized rates (ASRs) for 2024 for all cancers and the 10 most common cancer sites. We fitted a linear regression to the most recent trend segment identified by the joinpoint model. The number of avoided deaths since the peak in 1988-2024 was estimated for all cancers and CRC.

Results: We predicted 1 270 800 cancer deaths for 2024 in the EU, corresponding to ASRs of 123.2/100 000 men (-6.5% versus 2018) and 79.0/100 000 women (-4.3%). Since 1988, about 6.2 million cancer deaths have been avoided in the EU and 1.3 million in the UK. Pancreatic cancer displayed unfavorable predicted rates for both sexes (+1.6% in men and +4.0% in women) and lung cancer for women (+0.3%). The focus on CRC showed falls in mortality at all ages in the EU, by 4.8% for men and 9.5% for women since 2018. The largest declines in CRC mortality are predicted among those 70+ years old. In the UK, projected ASRs for CRC at all ages are favorable for men (-3.4% versus 2018) but not for women (+0.3%). Below age 50 years, CRC mortality showed unfavorable trends in Italy and the UK, in Poland and Spain for men, and in Germany for women.

Conclusions: Predicted cancer mortality rates remain favorable in the EU and the UK, mainly in males due to earlier smoking cessation compared to females, underlining the persisting major role of tobacco on cancer mortality in Europe. Attention should be paid to the predicted increases in CRC mortality in young adults.

Citing Articles

Cancer burden in Europe: a systematic analysis of the GLOBOCAN database (2022).

Elmadani M, Mokaya P, Omer A, Kiptulon E, Klara S, Orsolya M BMC Cancer. 2025; 25(1):447.

PMID: 40075331 PMC: 11905646. DOI: 10.1186/s12885-025-13862-1.


Potential prognostic biomarker of OSBPL10 in pan-cancer associated with immune infiltration.

Qi J, Yu K, Liu B, Wang Y, Wang W, An R Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40074843 DOI: 10.1007/s00210-025-03998-z.


Prevalence trend and burden of foodborne trematodiasis in China from 1990 to 2021 and its predictions until 2030: a comparative study with Japan and South Korea.

Ma R, Li N, Chen C, Lan J, Guo H, Zhang W Front Public Health. 2025; 13:1504218.

PMID: 40066009 PMC: 11891204. DOI: 10.3389/fpubh.2025.1504218.


The Relevance of Sex and Age as Non-Modifiable Risk Factors in Relation to Clinical-Pathological Parameters in Colorectal Cancer.

Barna R, Dema A, Jurescu A, Vaduva A, Lazureanu D, Vita O Life (Basel). 2025; 15(2).

PMID: 40003565 PMC: 11856218. DOI: 10.3390/life15020156.


The impact of SEC23A on 5-FU chemotherapy sensitivity and its involvement in endoplasmic reticulum stress-induced apoptosis in colorectal cancer.

Su Z, Liu M, Krohn M, Schwarz S, Linnebacher M Apoptosis. 2025; .

PMID: 39904858 DOI: 10.1007/s10495-025-02084-2.